BioCentury
ARTICLE | Clinical News

Golvatinib: Phase I data

June 4, 2012 7:00 AM UTC

A dose-escalation Phase I trial in 34 patients with advanced solid tumors showed that once-daily 100-450 mg golvatinib produced 6 cases of stable disease. The MTD was once-daily 400 mg golvatinib. Dos...